Frédéric Mascha, the founder


Frédéric MASCHA holds an MBA from Harvard Business School (Boston, USA) and graduated from the Institut Supérieur de Gestion in Paris (France).

Former Principal Partner at McKinsey & Co, Frédéric MASCHA has developed numerous strategies on behalf of large global pharmaceutical groups. In particular, it has made it possible to optimize the launch of several drugs dedicated to the treatment of disorders of the central nervous system, diabetes, cardiovascular diseases and gastrointestinal pathologies.

From LynaPharm to Juvisé Pharmaceuticals

Juvisé Pharmaceuticals is a young international company marketing these own pharmaceutical specialties.


LynaPharm from 2002 to 2008

In 2002, Frédéric MASCHA created the pharmaceutical company LynaPharm, in association with the Italian pharmaceutical group, Sigma-Tau.

Frédéric Mascha and his Juvisé group then sold all of their shares in LynaPharm to the Italian pharmaceutical group, Sigma-Tau, in 2008.

LynaPharm is a pharmaceutical company specializing in psychiatric disorders and markets in particular Lysanxia® (prazepam), Anafranil® (clomipramine hydrochloride) and Synedil® (sulpiride) in France and in many African countries.

Juvisé Pharmaceuticals


Juvisé Pharmaceuticals, since 2008

Following the sale of LynaPharm to the Sigma-Tau group in 2008, Frédéric MASCHA created Laboratoires Juvisé Pharmaceuticals.

An international healthcare player, Juvisé Pharmaceuticals is committed to defending and enhancing drugs with high therapeutic value for the well-being of patients in 57 countries around the world.

The Juvisé Pharmaceuticals laboratory currently markets 8 pharmaceutical specialties for the management of cardiac, psychiatric, rheumatological and respiratory / ENT * pathologies: Esidrex® (hydrochlorothiazide), Sintrom® (acenocoumarol), Digoxine-Juvisé® (digoxin), Entumin ® (clotiapine), Insidon® (opipramol), Lumirelax® (methocarbamol), Calmixene® (pimethixene) and Extovyl® (mesilate betahistine).

* ENT: Otorhinolaryngology

Contact Juvisé Pharmaceuticals

This site is registered on wpml.org as a development site.